Lithuania IVD Market: By Technology Molecular Diagnostics, Cytomegalovirus, Epstein–Barr virus, Tuberculosis, Sexually Transmitted Diseases, Hospital Acquired Infections, Respiratory Infections, Human Papillomavirus, Covid- 19), By Tissue Diagnostics, By Sequencing Region Forecast 2020-2031

Lithuania IVD Market: By Technology Molecular Diagnostics (Hepatitis C, Hepatitis B, Human Immunodeficiency Virus (HIV), Cytomegalovirus (CMV), Epstein–Barr virus (EBV), Tuberculosis, Sexually Transmitted Diseases (STDs), Hospital Acquired Infections, Respiratory Infections, Human Papillomavirus (HPV), Covid- 19), By Tissue Diagnostics (H&E Stains, Special Stains, Advanced Stains, Digital Scanners), By Sequencing (Clinical, NIPT and Research Use Only) Region Forecast 2020-2031

Lithuania IVD market size was valued at US$ X million in 2024 and is expected to reach US$ X million by 2031, growing at a significant CAGR of X% from 2025-2031. The Lithuania in-vitro diagnostics (IVD) market is a dynamic and rapidly evolving sector within the healthcare industry. IVD refers to medical devices and diagnostic techniques that are used to analyze samples derived from the human body, such as blood, urine, and tissue, outside the body. These tests provide crucial information for the early detection, diagnosis, and management of diseases and conditions. Molecular diagnostics in IVD market are growing at fastest rate due to increasing prevalence of various diseases such as Hepatitis B and C, Human Immunodeficiency Virus (HIV), Cytomegalovirus (CMV), Epstein–Barr virus (EBV), Tuberculosis, Sexually Transmitted Diseases (STDs), Hospital Acquired Infections, Respiratory Infections, Human Papillomavirus (HPV) and Covid- 19.

In Lithuania, regular screening for blood donations is mostly done with NAT-based assays. Hepatitis C testing is also done on other demographic groups, such as medical staff, military people, and pregnant women, and is frequently done as part of clinical and scientific research. Every year, 1,500-2,000 persons in Lithuania infect with Hepatitis B, with around 100 of them developing jaundice. Within 6 months of developing acute viral hepatitis B, 90-98 percent of individuals recover fully and develop natural immunity. 5% of persons infected with HBV become chronic carriers, producing HBsAg and HBV-DNA on a long-term basis, and these infected donors are diagnosed by serology and NAT. HIV infections were reported in practically all administrative units of 60 municipalities in Lithuania.

According to the ECDC report 2021, the number of newly diagnosed HIV cases gradually increased till 2017 and a downward trend was observed from 2017 to 2020. In 2017, the 263 new cases were recorded, and it reached to 108 cases by the end of 2020. Hospital-acquired infection is very high in Lithuania. Surgical site infections, catheter-associated urinary tract infections, ventilator-associated pneumonia, and healthcare-associated pneumonia, infections linked with endoscopic treatments, and Clostridium difficile infections are the most common hospital-acquired infections in Lithuania.

Lithuania IVD Market Dynamics

In Lithuania, high growth areas in infectious diseases are HPV, STDs, Respiratory Infections, Hospital Acquired infections (HAIs) and oncology markers. Tissue diagnostics and sequencing in Lithuania IVD market also accounted for the high market value. The prevalence of various diseases and investment in healthcare infrastructure are driving market growth. Human papillomavirus (HPV) is a prevalent sexually transmitted infection (STI) linked to cervical cancer. The increasing awareness about the importance of HPV vaccination and its effectiveness in preventing cervical cancer has led to a higher demand for screening and diagnostic tests for HPV in Lithuania.

Sequencing is a set of procedures for determining the fundamental structure of an unbranched biopolymer (DNA, RNA, protein, or carbohydrate), which results in a symbolic linear representation of the monomeric subunits that summarizes most of the molecule's atomic structure. In 2022, 18,901 sequencing tests are carried out in Lithuania. Majority of the sequencing tests are research use only and clinical has little share in the sequencing testing.  NIPT is gaining attention across the country owing to its non-invasive nature. Non-invasive prenatal testing (NIPT), using cell-free fetal DNA, has increasingly been adopted as a screening tool for fetal aneuploidies.

Lithuania IVD Market Segmentation Analysis

Report Benchmarks

Details

By Technology

  • Molecular Diagnostics
  • Tissue Diagnostics
  • Sequencing

Key Features of the Report

  • The lithuania ivd market report provides granular level information about the market size, regional market share, historic market (2020-2024), and forecast (2025-2031)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis

Download Free Sample Report

Frequently Asked Questions

Lithuania IVD market size was valued at US$ X million in 2024 and is expected to reach US$ X million by 2031, growing at a significant CAGR of X% from 2025-2031.

The key players of the market are QIAGEN, Bio-Rad Laboratories, Interlab Services, Roche Diagnostics, Thermofisher Scientific, Seegene, Inc., Cepheid, Inc., Abbott, Inc., Illumina, Inc., Dako, Leica, and Abbott

Molecular diagnostics technology is expected to drive market growth due to fast and accurate results. sequencing accounted for the 2nd highest market value of Euro 5.8 Mn in 2022 and is expected to reach Euro 7.5 Mn by 2029. In 2022, 18,901 sequencing tests are carried out in Lithuania.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1.Executive Summary
2.Global Lithuania IVD Market Introduction 
2.1.Global Lithuania IVD Market  - Taxonomy
2.2.Global Lithuania IVD Market  - Definitions
2.2.1.Technology
2.2.2.Region
3.Global Lithuania IVD Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Lithuania IVD Market Analysis, 2020 - 2024 and Forecast 2025 - 2031
4.1.  Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Lithuania IVD Market  By Technology, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
5.1. Molecular Diagnostics
5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Tissue Diagnostics
5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Sequencing
5.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
6.Global Lithuania IVD Market  By Region, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
6.1. North America
6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Europe
6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Asia Pacific (APAC)
6.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Middle East and Africa (MEA)
6.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Latin America
6.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
7.North America Lithuania IVD Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
7.1. Technology Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
7.1.1.Molecular Diagnostics
7.1.2.Tissue Diagnostics
7.1.3.Sequencing
7.2.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
7.2.1.United States of America (USA)
7.2.2.Canada
8.Europe Lithuania IVD Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
8.1. Technology Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.1.1.Molecular Diagnostics
8.1.2.Tissue Diagnostics
8.1.3.Sequencing
8.2.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.2.1.Germany
8.2.2.France
8.2.3.Italy
8.2.4.United Kingdom (UK)
8.2.5.Spain
9.Asia Pacific (APAC) Lithuania IVD Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
9.1. Technology Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Molecular Diagnostics
9.1.2.Tissue Diagnostics
9.1.3.Sequencing
9.2.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.China
9.2.2.India
9.2.3.Australia and New Zealand (ANZ)
9.2.4.Japan
9.2.5.Rest of APAC
10.Middle East and Africa (MEA) Lithuania IVD Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
10.1. Technology Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Molecular Diagnostics
10.1.2.Tissue Diagnostics
10.1.3.Sequencing
10.2.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.GCC Countries
10.2.2.South Africa
10.2.3.Rest of MEA
11.Latin America Lithuania IVD Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
11.1. Technology Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Molecular Diagnostics
11.1.2.Tissue Diagnostics
11.1.3.Sequencing
11.2.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Brazil
11.2.2.Mexico
11.2.3.Rest of LA
12. Competition Landscape
12.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
12.2.1.QIAGEN
12.2.2.Bio-Rad Laboratories
12.2.3.Interlab Services
12.2.4.Roche Diagnostics
12.2.5.Thermofisher Scientific
12.2.6.Seegene, Inc.
12.2.7.Cepheid, Inc.
12.2.8.Abbott, Inc.
12.2.9.Illumina, Inc.
12.2.10.Dako
12.2.11.Leica
12.2.12.Abbott
13. Research Methodology 
14. Appendix and Abbreviations 

Key Market Players

  • QIAGEN
  • Bio-Rad Laboratories
  • Interlab Services
  • Roche Diagnostics
  • Thermofisher Scientific
  • Seegene, Inc.
  • Cepheid, Inc.
  • Abbott, Inc.
  • Illumina, Inc.
  • Dako
  • Leica
  • Abbott

Related Industry Reports